Alnylam Achieves First Annual Profit with 81% Product Revenue Growth, Driven by AMVUTTRA Expansion and Pipeline Progress

summarizeSummary

Alnylam Pharmaceuticals reported its first annual net income in 2025, driven by an 81% surge in product revenues, primarily from AMVUTTRA, alongside significant pipeline advancements and strategic capital management.

check_boxKey Events

• Achieved First Annual Net Income

  The company reported a net income of $313.7 million for the year ended December 31, 2025, a significant turnaround from a net loss of $278.2 million in the prior year.

• Strong Product Revenue Growth

  Net product revenues increased by 81% to $2.99 billion in 2025, primarily driven by a 138% increase in AMVUTTRA sales to $2.31 billion, following its expanded regulatory approvals.

• Key Product Approvals and Pipeline Advancements

  AMVUTTRA received FDA approval in March 2025 and EC approval in June 2025 for ATTR amyloidosis with cardiomyopathy. Nucresiran and zilebesiran advanced into Phase 3 clinical trials, and cemdisiran showed positive Phase 3 results with a US regulatory submission planned for Q1 2026.

• Convertible Debt Refinancing and New Credit Facility

  Alnylam issued $661.3 million in 0.00% Convertible Senior Notes due 2028 and concurrently repurchased $672.2 million aggregate principal amount of its 2027 Notes for a total cost of $1.16 billion. The company also established a new $500 million revolving credit facility.

auto_awesomeAnalysis

Alnylam Pharmaceuticals reported a significant financial turnaround in its 2025 annual report, achieving its first-ever annual net income of $313.7 million, a substantial improvement from a net loss of $278.2 million in 2024. This strong performance was primarily fueled by an 81% increase in net product revenues, reaching nearly $3.0 billion, largely driven by the robust growth of AMVUTTRA sales, particularly following its FDA and EC approvals for ATTR amyloidosis with cardiomyopathy. The company also highlighted significant advancements across its pipeline, including the progression of nucresiran and zilebesiran into Phase 3 clinical trials and positive Phase 2 data for elebsiran. While the company undertook a substantial refinancing of convertible notes and disclosed ongoing legal matters, these were overshadowed by the strong operational and financial results, reinforcing a positive outlook for its 'Alnylam 2030' growth strategy. This 10-K provides the full audited details following the preliminary results announced in a concurrent 8-K filing.